TRANSGENOMIC INC – 10-Q – Management’s Discussion and Analysis of Financial Condition and Results of Operations
Edgar Online, Inc. |
Forward-Looking Information This report, including Management's Discussion & Analysis, contains forward-looking statements. These statements are based on management's current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees of performance or results. Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating expenses, supplier pricing, availability and prices of raw materials,Medicare /Medicaid /Insurance reimbursements, product pricing, foreign currency exchange rates, sources of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, industry conditions, our ability to execute our operating plans, the success of our cost savings initiatives, competitive environment and related market conditions, actions of governments and regulatory factors affecting our business and other risks as described in our reports filed with theSecurities and Exchange Commission . In some cases these statements are identifiable through the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "target," "can," "could," "may," "should," "will," "would" and similar expressions. You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons including those described in Part II, Item 1A, "Risk Factors," of this report and in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the fiscal year endedDecember 31, 2011 , which we filed with theSecurities and Exchange Commission onMarch 14, 2012 . We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The following discussion should be read together with our financial statements and related notes contained in this report and with the financial statements, related notes, and Management's Discussion & Analysis included in our Annual Report on Form 10-K for the fiscal year endedDecember 31, 2011 , which we filed with theSecurities and Exchange Commission onMarch 14, 2012 . Results for the three and nine months endedSeptember 30, 2012 are not necessarily indicative of results that may be attained in the future.
Overview
We are a global biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. We have three complementary business segments: •Clinical Laboratories . Our clinical laboratories specialize in genetic testing for cardiology, neurology, mitochondrial disorders, and oncology. Located inNew Haven, Connecticut andOmaha, Nebraska the molecular clinical reference laboratories are certified under the Clinical Laboratory Improvement Amendment (CLIA) as high complexity labs and ourOmaha facility is also accredited by theCollege of American Pathologists (CAP). • Pharmacogenomics Services. Our Contract Research Organization located inOmaha, Nebraska provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by our pharmaceutical customers. This lab specializes in pharmacogenomic, biomarker and mutation discovery research testing that serves the pharmaceutical and biomedical industries world-wide for disease research, drug and diagnostic development and 21
--------------------------------------------------------------------------------
Table of Contents
clinical trial support. The lab employs a variety of genomic testing service technologies including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and which enables detection of mutations from virtually any sample type including tissue biopsies, blood, and circulating tumor cells (CTCs) at levels greater than 1,000-fold higher than standard DNA sequencing techniques. • Diagnostic Tools. Our proprietary product is the WAVE® System which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. There is a worldwide installed base of more than 1,550 WAVE Systems as ofSeptember 30, 2012 . We also distribute bioinstruments produced by other manufacturers ("OEM Equipment") through our sales and distribution network. Service contracts to maintain installed systems are sold and supported by our technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. We develop, manufacture and sell these consumable products. In addition, we manufacture and sell consumable products that can be used on multiple, independent platforms. These products include SURVEYOR® Nuclease and a range of chromatography columns. In ourClinical Laboratories segment, one of our key products is our new proprietary C-GAAP (Clopidogrel Genetic Absorption Activation Panel ) test. In July of 2012, we successfully securedMedicare coverage for C-GAAP, which is a simple but comprehensive saliva test that accurately predicts whether or not a patient has the appropriate genetic make up to receive a therapeutic benefit from Plavix® (clopidogrel). This innovative test analyzes markers in two important genes to identify patients who are at a genetically increased risk of major adverse cardiovascular events due to diminished effectiveness of Plavix® (clopidogrel). As a result of this coverage, the 48 million Americans currently covered byMedicare will have access to this important genetic test. Plavix® is the most widely prescribed antiplatelet drug used to reduce the risks of death, stroke and heart attack in heart disease patients. Patients with dysfunctional CYP2C19 and ABCB1 genes treated with clopidogrel exhibit a 50% increase in major adverse cardiovascular event rates than do patients with normal CYP2C19 and ABCB1 genetic function.Transgenomic's C-GAAP is the only one on the market that includes both genes in the test. In September, we announced the completion of the acquisition of global rights to the ScoliScore™ Adolescent Idiopathic Scoliosis (AIS) Prognostic Test from Axial Biotech. This acquisition providesTransgenomic with the ScoliScore™ assay technology and intellectual property, an established revenue and customer base, and access to a testing market estimated at more than 400,000 patients inthe United States alone. ScoliScore™ is the first clinically validated and commercially available saliva-based multi-gene test that provides a highly accurate assessment of the likelihood of spinal curve progression for individuals diagnosed with AIS, or an abnormal lateral curve of the spine. ScoliScore™ has the ability to identify patients that will not progress to a severe curvature of the spine and reduces those patients' need for repeated doctor visits, and more importantly, years of exposure to radiation from frequent X-Rays which significantly increases these patients' risk for cancer. The health economic benefits of the ScoliScore™ Test are considerable for patients, physicians, and payors, when taking into account the time and expense associated with repeated radiography and the costs related to treating AIS. ScoliScore™ is emblematic of the kind of value-added, proprietary genetic test thatTransgenomic seeks to provide to patients. In August, we announced a new commercial collaboration with theMedical College of Wisconsin Laboratories (MCW), a world-renowned institution with a robust presence in genomics and genetic testing. In addition to traditional sequencing services, MCW is the first lab to offerTransgenomic's proprietary NuclearMitome Test which employs next-generation sequencing technology to identify mutations in 448 genes and, to date, represents the most comprehensive genetic test available for mitochondrial disorders. Mitochondrial disorders are notoriously difficult to diagnose because they affect multiple organ systems, including the liver, the brain and nervous system, kidneys, and cardiovascular system. We expect that MCW will commence processing commercial tests in the 4th quarter of 2012. In ourPharmacogenomics Services Unit , we continue to perform cancer pathway gene mutation analysis and other associated genomics service testing for a number of pharmaceutical companies: both for pre-clinical drug discovery projects and phase II and III clinical trials. ICE COLD-PCR enables detection of mutations from virtually any sample type including tissue biopsies, blood, and circulating tumor cells (CTCs). The broad use of this innovative technology has the potential to benefit cancer screening, diagnosis, monitoring, and therapy selection since it has the ability to perform safer, less invasive, and more frequent assessments of a cancer and its mutations, all through a simple blood draw. In addition to our on-going study in several cancer types with MD Anderson, we have initiated two new collaborations for clinical validation of our advanced platform technology. ? Collaboration withNYU Langone Medical Center to better understand molecular events that drive non-small cell lung cancer and validate the use of ICE COLD-PCR mutation detection in blood (which we refer to as a "blood biopsy") for determining the appropriate response to existing and novel therapies in NSCLC. 22
--------------------------------------------------------------------------------
Table of Contents
? Collaboration with theUniversity of Nebraska Medical Center for employing ICE COLD-PCR for the early detection of Pancreatic Cancer.Transgenomic was awarded an NIH STTR Grant to support this work. The breakthrough ICE COLD-PCR technology, exclusively licensed byTransgenomic for DNA sequencing analysis, was developed in collaboration with theDana-Farber Cancer Institute and is supported by multiple validation studies confirming reproducible mutation detection up to 1,000 to 10,000 times more sensitive than traditional sequencing techniques and significantly improves the detection of mutations in biological samples. The technology is also being evaluated in an ongoing study with The University of Texas MD Anderson Cancer Center to characterize tumor-derived DNA in blood and DNA isolated from circulating tumor cells (CTCs) from patients with a variety of cancers to choose therapies shown to target specific mutations. Finally, in September, we announced the appointment ofMark P. Colonnese as Executive Vice President and Chief Financial Officer ofTransgenomic .Mr. Colonnese has nearly 30 years of experience in leading business growth and financial strategies for life sciences companies. In this new role,Mr. Colonnese will be a key player inTransgenomic's expansion through strategic corporate development, new collaborations, and future acquisitions. He will also lead our financial and capital markets strategy and advise on business development and transactional activities. Uncertainties We have historically operated at a loss and have not consistently generated sufficient cash from operating activities to cover our operating and other cash expenses. We have been able to historically finance our operating losses through borrowings or from the issuance of additional equity. AtSeptember 30, 2012 we had cash, cash equivalents and short term investments of$8.7 million . We believe that existing sources of liquidity are sufficient to meet expected cash needs for at least the next 12 months. The uncertainty of the current general economic conditions could negatively impact our business in the future. There are many factors that affect the market demand for our products and services that we cannot control. Demand for our Diagnostic Tools business is affected by the needs and budgetary resources of research institutions, universities and hospitals. The instrument purchase represents a significant expenditure by these types of customers and often requires a long sales cycle. These customers may not have the funding available to purchase our instruments. Competition and new instruments in the marketplace also may impact our sales. We have translation risk that occurs when transactions are consummated in a currency other than British Pound Sterling, which is the functional currency of our foreign subsidiary. These transactions, which are most often consummated in Euros, must be translated into British Pound Sterling. In addition, results of operations and the balance sheet of our foreign subsidiary are translated from British Pound Sterling to our reporting currency, which is the U.S. Dollar. As a result we are subject to exchange rate risk. Fluctuations in foreign exchange rates could impact our business and financial results. 23
--------------------------------------------------------------------------------
Table of Contents
Results of Operations Net sales for the nine months ended
Three Months Ended
Dollars in Thousands Three Months Ended September 30, Change 2012 2011 $ % Clinical Laboratories $ 4,498 $ 4,085 $ 413 10 % Pharmacogenomics Services 220 552 (332 ) (60 )% Diagnostic Tools 3,171 3,616 (445 ) (12 )% Total Net Sales $ 7,889 $ 8,253 $ (364 ) (4 )%
Diagnostic Tools net sales of
24
--------------------------------------------------------------------------------
Table of Contents
Gross Profit. Gross profit and gross margins for each of our business segments were as follows: Dollars in Thousands Three Months Ended September 30, Margin % 2012 2011 2012 2011 Clinical Laboratories $ 2,385 $ 2,456 53 % 60 % Pharmacogenomics Services (38 ) 241 (17 )% 44 % Diagnostic Tools 1,453 1,748 46 % 48 % Gross Profit $ 3,800 $ 4,445 48 % 54 % Gross profit was$3.8 million , or 48% of total net sales during the third quarter of 2012, compared to$4.4 million , or 54% of total net sales during the same period of 2011. During the three months endedSeptember 30, 2012 , the gross margin forClinical Laboratories was 53% as compared to 60% in the same period of 2011. The change inClinical Laboratories gross margin is attributable to a change in the mix of tests performed and higher operating supplies, wages and software costs, which we are investing in a project to improve the efficiency of our lab operations. Pharmacogenomics Services gross margin decreased from 44% for the three months endedSeptember 30, 2011 to (17)% for the three months endedSeptember 30, 2012 . Pharmacogenomics Services has a relatively fixed-cost base and any increase or decrease in revenue directly impacts gross margins. Diagnostic Tools gross margin decreased to 46% for the three months endedSeptember 30, 2012 from 48% in the same period of 2011 due to the mix of instruments sold. Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, and facility costs. In addition, the effects of foreign currency revaluation are included in selling, general and administrative expenses. Our selling, general and administrative costs increased$1.2 million to$5.6 million from$4.4 million during the three month period endedSeptember 30, 2012 compared to the same period in 2011. We had higher bad debt expenses and stock compensation costs during the three months endedSeptember 30, 2012 . We also had higher recruiting fees, which were incurred to increase the size of our sales force to support C-GAAP and the launch of ScoliScoreTM, and higher marketing materials expenses. Included in our selling, general and administrative expenses for the three month period endedSeptember 30, 2012 were$0.1 million in costs related to our acquisition of the ScoliScoreTM test from Axial. Research and Development Expenses. Research and development expenses primarily include personnel costs, intellectual property fees, outside services, collaboration expenses, supplies, and facility costs and are expensed in the period in which they are incurred. For the three months endedSeptember 30, 2012 and 2011, these costs totaled$0.7 million and$0.5 million , respectively. Research and development expenses totaled 8% and 6% of net sales during the three months endedSeptember 30, 2012 and 2011, respectively. Other Income (Expense). Other expense for the three months endedSeptember 30, 2012 and 2011 includes interest expense of$0.2 million . Income Tax Expense (Benefit). Income tax expense for the three months endedSeptember 30, 2012 was$0.1 million , primarily related to income reported in the financial statements of our foreign subsidiary. Income tax benefit for the three months endedSeptember 30, 2011 was nominal. 25
--------------------------------------------------------------------------------
Table of Contents
Nine Months Ended
Dollars in Thousands Nine Months Ended September 30, Change 2012 2011 $ %
9,661 10,141 (480 ) (5 )% Total Net sales $ 24,188 $ 23,400 $ 788 3 %
Diagnostic Tools net sales of
Dollars in Thousands Nine Months Ended September 30, Margin % 2012 2011 2012 2011 Clinical Laboratories $ 6,693 $ 6,787 50 % 59 % Pharmacogenomics Services 418 764 35 % 42 % Diagnostic Tools 4,355 5,601 45 % 55 % Gross Profit $ 11,466 $ 13,152 47 % 56 %
Gross profit was
26
--------------------------------------------------------------------------------
Table of Contents
Pharmacogenomics Services gross margin decreased from 42% for the nine months endedSeptember 30, 2011 to 35% for the nine months endedSeptember 30, 2012 . Pharmacogenomics Services has a relatively fixed-cost base and any increase or decrease in revenue directly impacts gross margins. Diagnostic Tools gross margin decreased to 45% in the nine months endedSeptember 30, 2012 from 55% in the nine months endedSeptember 30, 2011 due to the mix of instruments sold. Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, and facility costs. In addition, the effects of foreign currency revaluation are included in selling, general and administrative expenses. Our selling, general and administrative costs increased$1.6 million from$14.3 million to$15.8 million during the nine month period endedSeptember 30, 2012 compared to the same period in 2011. We had higher bad debt expense, marketing materials and employment fees , partially offset by lower stock compensation costs for the nine months endedSeptember 30, 2012 as compared to the same period of 2011. Included in our higher outside services for the nine month period endedSeptember 30, 2012 were the costs related to our acquisition of the ScoliScoreTM test of$0.1 million . Research and Development Expenses. Research and development expenses primarily include personnel costs, legal fees, outside services, collaboration expenses, supplies, and facility costs and are expensed in the period in which they are incurred. For the nine months endedSeptember 30, 2012 and 2011, these costs totaled$1.9 million and$1.7 million September 30, 2012 and 7% during the same period in 2011. Other Income (Expense). Other expense for the nine months endedSeptember 30, 2012 and 2011 includes interest expense of$0.7 million and the income associated with the change in fair value of our Common Stock Warrant Liability of$1.0 million . Other expense in 2011 also includes the expense associated with the change in fair value of the Preferred Stock conversion feature and warrants of 6.9 million. The income or expense associated with the change in fair values of our Common Stock Warrant Liability and the preferred stock conversion feature and warrants are non-cash items. Income Tax Expense (Benefit). Income tax expense for the nine months endedSeptember 30, 2012 was$0.1 million . This is primarily comprised of taxes on income earned by our foreign subsidiary. Income tax benefit for the nine months endedSeptember 30, 2011 was$0.1 million . Liquidity and Capital Resources Our working capital positions atSeptember 30, 2012 andDecember 31, 2011 were as follows: Dollars in Thousands September 30, December 31, 2012 2011 Change Current assets (including cash, cash equivalents and short term investments of $8,745 and $4,946, respectively) $ 22,494 $ 17,198 $ 5,296 Current liabilities 16,600 16,328 272 Working capital $ 5,894 $ 870 $ 5,024
On
27
--------------------------------------------------------------------------------
Table of Contents
we will pay an additional
Analysis of Cash Flows Nine Months EndedSeptember 30, 2012 and 2011 Net Change in Cash and Cash Equivalents. Cash and cash equivalents decreased by$0.2 million during the nine months endedSeptember 30, 2012 compared to a decrease of$2.0 million during the nine months endedSeptember 30, 2011 . During the nine months endedSeptember 30, 2012 we used cash of$7.8 million in operating activities,$8.4 million in investing activities, which was offset by cash provided by financing activities of$15.9 million . In the nine months endedSeptember 30, 2011 , net cash used in operating activities was$0.9 million ,$0.4 million was used in investing activities and$0.8 million was used in financing activities. Cash Flows Used In Operating Activities. Cash flows used in operating activities totaled$7.8 million during the nine months endedSeptember 30, 2012 compared to cash flows used in operating activities of$0.9 million during the nine months endedSeptember 30, 2011 . The cash flows used in operating activities in 2012 include the net loss, increase in accounts receivable of$2.2 million and decrease in accounts payable of$1.1 million , offset by non-cash items including the warrant revaluation of$1.0 million , provision for losses on doubtful accounts of$1.6 million , stock option expense of$0.6 million and depreciation and amortization of$1.6 million . The cash flows used in operating activities in 2011 include the net loss and increase in accounts receivable of$1.4 million , offset by the non-cash items, which include revaluation of the preferred stock conversion feature and warrant liability of$6.9 million , provision for losses on doubtful accounts of$1.4 million and depreciation and amortization of$1.5 million . Cash Flows Used In Investing Activities. Cash flows used in investing activities totaled$8.4 million during the nine months endedSeptember 30, 2012 compared to cash flows used in investing activities of$0.4 million during the same period of 2011. Cash flows used in investing activities in 2012 included purchases of short term investments of$9.0 million , acquisition of ScoliScoreTM assets of$3.4 million , purchases of property and equipment of$0.6 million and additions to our patents of$0.3 million , offset by proceeds from the sale of short term investments of$5.0 million . Cash flows used in investing activities in 2011 include purchases of property and equipment of$0.1 million and additions to our patents of$0.3 million . Cash Flows Provided by or Used in Financing Activities. Cash flows provided by financing activities were$15.9 million for the nine months endedSeptember 30, 2012 . Cash provided by financing activities during the nine months endedSeptember 30, 2012 included the proceeds from the issuance of 19.0 million shares of our common stock and from the issuance of our common stock in connection with the exercise of stock options for 20,000 shares. Cash flows used in financing activities were for payments on debt and capital lease obligations. Cash flows used in financing activities were$0.8 million for the nine months endedSeptember 30, 2011 . Cash flows used in financing activities were for payments on debt and capital lease obligations offset by the cash received from issuance of common stock in connection with the exercise of stock options for 10,000 shares during the first nine months of 2011.
Off-Balance Sheet Arrangements At
Critical Accounting Policies and Estimates Accounting policies used in the preparation of the consolidated financial statements may involve the use of management judgments and estimates. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial statements and they require significant or complex judgments on the part of management. Our judgments and estimates
28
--------------------------------------------------------------------------------
Table of Contents
are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. Our critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended
Recently Issued Accounting Pronouncements Please refer to our Annual Report on Form 10-K for the fiscal year ended
Impact of Inflation We do not believe that price inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.
Wordcount: | 5358 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News